Navigation Links
New Cancer Treatment Shrinks Pancreatic Tumor
Date:11/23/2008

NASHVILLE, Tenn., Nov. 24 /PRNewswire/ -- A new cancer treatment is realizing outstanding results against pancreatic cancer. Following five weeks of treatment, a patient's large, stage 4 tumor was reduced in size by 70%. After seven more weeks of treatment, it no longer could be definitely identified on scans. Pancreatic cancer usually is fatal six to nine months after diagnosis. NeoPlas Innovation's combination of FDA-approved drugs appears to improve those odds for some patients, based on this result and similar ones seen before the protocol's public availability.

The tumor reduction correlated with resolution of the patient's symptoms of pain and digestive problems. "The cancer isn't gone," emphasized NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell. "There are still several metastatic lesions to address, but this kind of response is virtually unheard of in pancreatic cancer. At the very least, we're looking at his having many, many months of added survival with a quality of life he can truly enjoy."

The patient's daughter discussed her father's treatment, saying "He began the NeoPlas treatment after he became too ill to complete his final course of radiation following chemotherapy." She added, "Since then, he has been able to resume work two to three hours a day, go to lunch with other men and even take a ten-day trip to Europe with my brother."

The cholesterol drug Lovastatin is a key part of this treatment that has arrested or eradicated tumors in 78% of initial patients. The first person treated with the investigative protocol in 2000 had stage 4 melanoma; he remains disease-free today.

Based on experience and relevant lab research to date, staff members expect the best results for several malignancies. In addition to pancreatic cancer and melanoma, they include colon cancer, renal (kidney) cancer, mesothelioma, and a group of sarcomas, including osteosarcoma, chondrosarcoma and malignant fibrous histiocytoma.

Fatigue is the most notable side effect of NeoPlas Innovation's cancer treatment. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors the outpatient treatment.

A web site, http://www.neoplas.org, provides answers to common questions and a screening tool. Individuals can reach NeoPlas at 615-371-8100 or by e-mailing office@neoplas.org.

For an interview with Dr. Cantrell, call 615-371-8100 or e-mail office@neoplas.org.


'/>"/>
SOURCE NeoPlas Innovation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
2. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
3. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
4. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
5. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
6. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
7. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
8. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
9. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
10. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
11. NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology:
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):